Physician profile
John A Posey, JR.
NPI 1043216203
$2,236.93
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,600 · 2020: $449 · 2021: $188.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $352.68 | 2019-2021 | |
| Amarin Pharma, INC. | $287.07 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $224.37 | 2019-2021 | |
| Novo Nordisk INC | $191.40 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.27 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $128.18 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $125.91 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $104.09 | 2019-2020 | |
| Abbott Laboratories | $97.97 | 2019 | |
| Abbvie INC. | $94.98 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $77.22 | 2019-2020 | |
| Allergan, INC. | $67.90 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.52 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.05 | 2019-2021 | |
| Sanofi Pasteur INC. | $42.82 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $27.37 | 2019-2021 | |
| Titan Spine, LLC | $24.22 | 2019 | |
| Gilead Sciences, INC. | $23.75 | 2019 | |
| Assertio Therapeutics, INC. | $19.01 | 2020 | |
| Genentech USA, INC. | $18.04 | 2019 | |
| Vanda Pharmaceuticals INC. | $17.99 | 2019 | |
| Shire North American Group INC | $14.75 | 2019 | |
| Amgen INC. | $14.48 | 2019 | |
| Pfizer INC. | $13.37 | 2019 | |
| Amneal Pharmaceuticals LLC | $11.31 | 2019 | |
| Lilly USA, LLC | $11.21 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Posey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.